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Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) 
could be associated with a reduced risk of infection compared to standard allogeneic HCT. We 
retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with 
low-dose TBI +/- fludarabine and postgrafting CsA and MMF. The proportion of patients with any 
infection was 77%, but the majority of infectious events occurred beyond day 30. Donor other than 
sibling, older age, early disease and male gender were significant risk factors. The incidence of 
bacteraemia was 55% at 1 yr and the number of bacteraemic episodes was 0.9 per patient (0.08 before 
day 30). The risk of bacteraemia increased with older age and the use of a donor other than an HLA-
identical sibling, but not with neutropenia. The incidence of infections other than bacteraemia 
correlated with the use of corticosteroids. The risk of CMV infection increased with high-risk CMV 
serology, and risk of CMV disease with high-risk CMV serology, older age, first transplantation and a 
diagnosis of lymphoma. In conclusion, after NMSCT, infections are not frequent in the first 30 days 
post-transplant but careful long-term monitoring is necessary thereafter. 
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Allogeneic hematopoietic stem cell transplantation (allo-HCT) with a myeloablative 
conditioning remains the only curative treatment for several haematological malignancies1. However, 
because of its toxicity, this approach is restricted to younger and fitter patients. This observation led 
several groups to set up transplant protocols with a nonmyeloablative conditioning (NMSCT for 
“nonmyeloablative stem cell transplantation”) in which elimination of malignant cells is shifted from 
the preparative regimen to the GVL effect2, 3. The Seattle team has proposed an original approach to 
NMSCT with a conditioning regimen based on single dose (2 Gy) TBI +/- fludarabine (90 mg/m2), 
followed by post-transplant immunosuppression with cyclosporine A (CsA) and mycophenolate 
mofetil (MMF) that permitted to perform the transplant in an ambulatory care setting4-6. The authors 
observed a low transplant-related mortality (even in older patients), which was most often attributed to 
graft-versus-host disease (GVHD) and/or infections5, 6. Thus, one major objective to improve outcome 
following NMSCT is to achieve rapid immune reconstitution (to permit the occurrence of the GVL 
effect7 and avoid opportunistic infections), without severe GVHD.  
Infections represent up to 63% of causes of death in standard allogeneic transplant recipients at 
the time of autopsy8. Theoretically, NMSCT could be associated with a reduced risk of infection 
because they cause less disruption of the gastrointestinal mucosa 9-11 and less severe neutropenia9, 12, 13. 
In addition, the prolonged presence of host immunity could provide some protection against infectious 
events14. However, it is not yet clear whether NMSCT would indeed result in a reduced risk of 
infection compared to standard myeloablative allogeneic transplantation. Available data have 
sometimes indicated a reduced incidence of infection after NMSCT9, 10 but other studies have observed 
similar rates of infection after the two forms of allogeneic transplantation11, 12, 15-18. We therefore 
conducted a retrospective study to describe the incidence and types of infection in 62 recipients of a 




Patients and methods 
 
Patients 
Patients’ characteristics are described in Table 1. The study population included 62 consecutive 
patients, 16 females and 46 males, aged 54±11 yrs (M±SD), who had undergone NMSCT between 
March 2000 and May 2003. NMSCT were performed in patients deemed unfit for HCT with 
myeloablative conditioning  because of age (> 55 yrs for sibling or > 50 yrs for UD transplants), 
comorbidity (poor organ function or active infection) or relapse after a conventional transplant. Among 
them, 55 had haematological malignancies and 7 had renal cell carcinoma, one-third in early disease 
(untreated or 1st partial (PR) or complete (CR) remission) and two-thirds in more advanced stages. The 
donor was an HLA-identical sibling in about 50% of the cases and an alternative donor in the other 
50%. All patients on study were followed up for a minimum of 6 months or until death. Patients and 
donors gave written informed consent to the transplant procedure, as well as to the collection and 




 In accordance with the regimen developed by the Seattle team19, patients received low-dose 
TBI (2Gy) either alone (n=19) or with fludarabine (90mg/m2) (n=33),. Cyclophosphamide (3 g/m2) 
was substituted for TBI in case of previous irradiation precluding TBI (n=10). PBSC were mobilized 
with G-CSF 10 µg/kg/d. Graft manipulations consisted in CD8 depletion (n=28) or CD34 selection 
(n=7). An average dose of 5.7±2.9 x 106 CD34+ cells/kg was infused. Post-transplant 
immunosuppressive therapy was carried out with Cyclosporine A (CsA, from day –1 to day 180 or 
longer in case of alternative donor or chronic GVHD) and mycophenolate mofetil (MMF, 15 mg/kg 
b.i.d. from day -1 to day 28 or day 42 in case of alternative donor) as previously described14, 20. The 
diagnosis and grading of acute GVHD was established as previously reported21. First-line treatment of 
GVHD consisted in corticosteroids (2 mg/kg). G-CSF (5 µg/kg/d) was administered only when the 
 5
granulocyte count was below 1.0 x 109/L. Disease evaluation was routinely carried out on days 40, 
100, 180 and 365. All patients had a central venous catheter device. DLI were given either 
prophylactically after CD34 selection or in case of poor chimerism or relapse .   
 
Infection prophylaxis and treatment 
Patients also received acyclovir (400 mg t.i.d. orally), oral antifungal prophylaxis with 
itraconazole solution (200 mg b.i.d.) and aerosolized pentamidine, but no antibacterial prophylaxis, 
until the end of immunosuppressive therapy. In case of fever, above 38.3°C once or above 38°C on 
three consecutive measurements, empirical antibiotherapy was started with a combination of cefepime 
+ amikacin. Before the initiation of antibiotherapy, blood cultures were drawn through each lumen of 
the central catheter and a peripheral vein. Additional blood cultures were obtained when clinically 
indicated. Patients were weekly screened for CMV by antigenemia and PCR in blood. Pre-emptive 
therapy with ganciclovir was initiated after a positive antigenemia or PCR and discontinued after day 
100 and at least three consecutive negative results. 
 
Definitions 
According to the definitions of the Infectious Diseases Working Party of the EBMT, 
bacteraemia or fungemia were defined by the isolation of bacteria or fungi from any blood culture in 
the context of fever or other clinical signs consistent with infection22. For coagulase-negative 
staphylococci, at least two blood cultures with the same antimicrobial susceptibilities were required to 
be positive. Varicella-zoster virus (VZV) infections were defined as typical cutaneous vesicular lesions 
or atypical lesions associated with the detection of VZV by culture or IF. Any positive result in CMV 
screening tests was considered as CMV infection whereas CMV disease was defined by the evidence 
of CMV infection at one body site (PCR or histopathologic finding) in association with clinical signs 
or symptoms. Invasive fungal infections were defined according to the EORTC criteria23. Fever of 





Patients’ characteristics (Table 1) and proportions of patients with a given number of infections 
(Table 2) were analyzed by appropriate contingency tables. Times to infectious events were studied by 
Kaplan-Meier analyses. Univariate and multivariate Cox regression models were used to analyze the 
influence of selected variables on the risk of infection. Times to events were the outcomes, with 
censoring at time of subsequent transplant, death or last follow-up. Variables were selected with a 
forward stepwise procedure (criterion p<0.05) and P values were calculated with the likelihood ratio 
test. Statistical analyses were done using Microsoft Excel (Microsoft Corp., Redmond, WA), 





Types of infection  
No patient experienced toxic mucositis or significant gastrointestinal toxicity. The mean 
neutrophil nadir was 580/µL (range 0-3000). It 35 patients, the neutrophil count did not decrease 
below 500/µL. Patients received G-CSF for a mean of 5.5 (0-17) days. The median time to 1,000 
PMN/µL was 8.5 (1-22) days. There were 25 deaths (40%). Sixty percent of the deaths were due to 
relapse/progression of the underlying disease. Infection was the primary cause of death in 10% of the 
patients but infections contributed to death in 24% of them. The proportion of patients presenting any 
infection during the course of their follow-up was 77% (Table 2) but the majority of these first 
infections occurred well beyond day 30 post-transplantation (figure 1A).  
The actuarial incidence of bacteraemia at one year was 55% (Figure 1B). Overall, there were 
0.9 episode of bacteraemia/patient (Table 3). However, these bacteraemias were seldom (0.08 per 
patient at risk) observed in the first 30 days post-transplant. The largest number of bacteraemias was 
due to coagulase-negative staphylococci (41%). Gram-negative bacteria accounted for 25% of events. 
 7
Other agents causing bacteraemias included streptococci (9%), miscellaneous other bacteria (21%) and 
fungi (4%). The actuarial incidence at one year of infections other than bacteraemia was 72%, but 
again these infections were significantly delayed (Figure 1C). The major types of such infections were 
pneumonias and upper respiratory tract (URT) infections  (Table 3).   
 
Infectious agents 
Before day 30, the main agents responsible for infections were bacteria (N=18 (82%)) and that 
dominance persisted throughout the observation period (Table 3). Again there was a low incidence of 
bacterial infections (n=17, 0.27/patient at risk) in the first 30 days following transplantation. 
Considering all infectious episodes, Gram-positive bacteria were the agents most frequently 
responsible for infection: Coagulase-negative staphylococci were involved in 24/132 events and 
streptococci in 10/132 events. Gram-negative bacteria were involved in 28/132 cases and 
miscellaneous other bacteria in 15/132 cases.  
Fungal infections represented an incidence of 0.03 event/patient at risk  before day 30, but their 
incidence tended to increase thereafter (0.10/patient at risk between days 100 and 365) (Table 3). 
Candidas were identified in 5% of infectious episodes, while aspergillus was documented in 7% of all 
infections. However, there was a further 3% incidence of possible fungal infections.  
The actuarial incidence of VZV infection was 10% at one year. The actuarial incidences of 
CMV infection and disease were 52% and 18%, respectively (Figure 2). No case of CMV reactivation 
or disease occurred among the low risk patients (donor and recipient serologically negative). After 
excluding low risk patients, rates of CMV infection and disease were 68% and 23%, respectively., i.e. 
36% and 9% in the intermediate risk group (donor seropositive and recipient seronegative), and 80% 
and 26%, in the high risk category (recipient seropositive) (Table 4).  
 
Risk factors for infection 
We then examined, in univariate and multivariate analysis, risk factors for infection, separately 
analyzing all infections, bacteraemias, infections other than bacteraemia, CMV infection and CMV 
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disease, interstitial pneumonia and VZV infection. These factors included data concerning the donor 
(relationship to patient, age, sex, ABO compatibility, CMV status), patient (age, sex, diagnosis, pre-
transplant disease status, CMV status), transplant procedure (conditioning regimen, consecutive 
number of the transplant, graft manipulation, use of DLI) and complications (neutropenia, aGVHD, 
cGVHD, use of corticosteroids). 
When looking at the overall risk of infection, we identified in univariate analysis donor other 
than HLA-identical sibling (p=0.0077) and absence of DLI as significant risk factors (p=0.0132). In 
multivariate analysis, only having a donor other than a HLA-identical sibling (p=0.0010) was a 
significant risk factor. 
For bacteraemia, in univariate analysis only donor source reached statistical significance, with a 
one-year 43% incidence of bacteraemia with a sibling donor and 66% with an alternative donor 
(p=0.0061). This result was confirmed in multivariate analysis (p=0.0015), where the risk of 
bacteraemia increased also with the age of the recipient (p=0.0064) . 
For infections other than bacteraemia, in univariate analysis only administration of DLI was 
associated with an increased risk (p=0.00440), whereas in multivariate analysis only the use of 
corticosteroids increased the risk (p=0.0066). 
In univariate analysis, only high-risk pretransplant CMV status (R+/D-, R+/D+) (p<0.0001) 
influenced the risk of CMV infection, which nevertheless tended to be higher in older patients 
(p=0.0721) and patients with donor other than HLA-identical sibling (p=0.0679). In multivariate 
analysis, the risk of CMV infection increased only with a high-risk CMV status (p<0.0001) and, 
among these patients, no additional factor was identified.  
Similarly, in univariate analysis, the risk of CMV disease increased in patients with high-risk 
pretransplant CMV status (p=0.0054). Among these patients, in multivariate analysis, the risk of CMV 
disease increased with the age of the patient (p=0.0137), a first transplantation (p=0.0057) and a 





  NMSCT are usually reserved for patients unable to undergo myeloablative conditioning 
because of older age, poor clinical condition or previous transplantation with a high-dose regimen. It is 
therefore impossible to select, for the purpose of comparison, an appropriately matched group of 
patients undergoing transplantation after a standard myeloablative conditioning. Compared to 
myeloablative regimens, nonmyeloablative conditioning is associated with less myelotoxicity and 
produces fewer extra-haematological toxicities, in particular less damage to the mucosal barriers of the 
gastrointestinal tract9-11, 24. However, the relative intensity of these treatments ranges from the reduced-
intensity conditioning (RIC) regimens that still induce severe neutropenia and are carried out in 
inpatient protected units10, 15, 25, 26, to the truly nonmyeloablative regimen developed by the Seattle 
team that causes little neutropenia, can be performed as outpatient and cause much less morbidity9, 12, 
13, 24
. Using the Seattle regimen, we indeed encountered virtually no toxic mucositis and no 
gastrointestinal toxicity. In addition, we have previously shown that this regimen was associated with 
little myelosuppression20 and with prolonged persistence of host immune cells14. However, it was not 
clear whether these factors had the potential of providing some protection against infections.  
In our population of 62 NMSCT recipients, the proportion of patients presenting any infection 
during follow-up was 77%. This overall proportion is quite similar to the one found after standard 
allogeneic transplantation20, 27, but the majority of these first infections occurred well beyond day 30 
post-transplantation (Figure 1A). Although earlier papers in small number of patients were widely 
discrepant in that respect11, 18, this reduced rate of early infection10 and this delayed time to first 
infection9, 10 in NMSCT recipients have also been described by others. Therefore, the absence of 
mucosal damage and of neutropenia in many NMSCT patients possibly did confer some protection 
against early infections in our patients. This is consistent with a previous study showing that 
neutropenia at initiation of a RIC is already a risk factor for subsequent infection in the early post-
transplant period15. However, in our hands, among NMSCT recipients, those with early neutropenia 
did not have a higher rate of early infection.  
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  Bacteria were evidently the leading agents causing infection. This was particularly true in the 
early post-transplant phase, but remained so thereafter as well, albeit to a lesser extend. Among them, 
Gram-positive bacteria were the agents most frequently responsible for infection, in agreement with 
data in standard allogeneic transplantation27-30 and probably related to the fact that all patients carried a 
central venous catheter device. Similarly, the pattern of fungal infections was consistent with previous 
studies9, 10 that reported incidences of proven or probable fungal infection in NMSCT recipients12, 16, 17 
comparable to those observed in standard transplants after a myeloablative conditioning31, 32. Some9, 12, 
16
 but not all17 previous studies have shown that advanced disease, age above 40, GVHD, 
corticosteroid use, CMV infection or relapse were predictive of fungal infections in NMSCT patients, 
but the number of patients with such infections in our series was too low to analyze these factors.  
  After excluding seronegative patients with a seronegative donor, the actuarial incidences of 
CMV infection and CMV disease were 68% and 23%, respectively. In some previous studies, CMV 
infection and disease have been delayed after NMSCT13, 33. It is hypothesized that residual host T 
lymphocytes may contribute to resistance to CMV disease and that, as the level of these cells decline 
over time, the risk of infection increases34. However, similarly to some other studies26, we did not 
observe any such delay in NMSCT recipients. On the other hand, the incidence of CMV infection and 
disease was clearly dependent on recipient and donor serostatus13, 17, 26, 33. In addition, older age and an 
alternative donor, but not the use of corticosteroids17, acute GVHD26, graft manipulation26 or use of 
fludarabine for conditioning35, tended to be risk factors for CMV infection. However, it cannot be 
excluded that the fact that CMV disease was more frequent after a first transplant may in fact in part be 
related to the use of fludarabine, as the vast majority of patients not receiving this drug were second 
transplants. Although this was not found for CMV infection, older age was indeed associated with 
CMV disease in multivariate analysis. It has also been suggested that the use of ATG or Campath-1H 
in the conditioning regimen25 or the use of MMF post-transplant36 could enhance the risk of CMV 
infection and disease, but this is not evaluable in our series. Chronic GVHD has been recognized as a 
significant risk factor after conventional allogeneic transplantation37, but not after NMSCT. 
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Bacteraemias occur in about 20% to 60% of the cases after allogeneic HCT28. In our study, the 
incidence of bacteraemia at one year was 55%. In addition, occurrence of bacteraemia was again 
delayed beyond the first 30 days. Contrarily to the findings of others using a similar conditioning 
regimen9, neutropenia was not a risk factor for bacteraemia. In agreement with others17, the agents 
responsible for bacteraemias were mainly coagulase-negative staphylococci, and in general, Gram-
positive bacteria were the agents most often responsible for infection. This result is totally in 
agreement with the literature17.   
A number of risk factors were consistently identified by univariate and multivariate analysis. 
Age above 60 years and use of an alternative donor were often associated with an increased risk of 
overall infection, bacteraemia, CMV infection and CMV disease. This has not been reported before in 
NMSCT patients, except for CMV infection, and could be related to poorer immune reconstitution or 
increased incidence of GVHD in those patients, although GVHD per se was not associated with an 
increased risk in our patients. In univariate analysis, absence of DLI was associated with an increased 
overall risk of infection. This probably reflects the fact that DLI were mostly given in case of 
transplantation with an HLA-identical sibling, but also that DLI may enhance immune recovery. For 
infections other than bacteraemia, only the use of corticosteroids significantly increased the risk. The 
influence of corticosteroids on the infectious risk is well described in the literature9, 11, 12, 16, 17, 35. The 
initial disease category gave inconsistent information, with lymphoma patients having more CMV 
disease. The use of TBI or graft manipulation were not linked to an increased risk of infection in our 
population.  
In conclusion, NMSCT recipients are at risk for the same type of infections with the same kind 
of pathogens than myeloablative transplant recipients. However, infections are less frequent in the first 
30 days post-transplant. Methods of prophylaxis, empirical antibiotic therapy and pre-emptive 
treatments should be the same as for conventional allografts. Careful long-term monitoring of these 
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Table 1.  Patients’ characteristics. 
Number 62 
Age (yrs) (M±SD) 54±11 
Sex  
     Female 16 (26%) 
     Male  46 (74%) 
Diagnosis  
     Leukaemia 23 (37%) 
     Lymphoma/myeloma 32 (52%) 
     Solid tumour 7 (11%) 
Status at transplant  
     Untreated 9 (14%) 
     CR   17 (28%) 
     PR  7 (11%) 
     Relapse/Resistant 29 (47%) 
Donor type 
     Sibling 30 (49%) 
     Other family 4 (6%) 
     Unrelated 28 (45%) 
VZV status (Recipient)  
     Positive 52 (84%) 
     Negative 10 (16%) 
CMV status (Recipient/Donor)  
     -/- 15 (24%) 
     -/+ 11 (18%) 
     +/- 20 (32%) 
     +/+ 16 (26%) 
Transplant number  
     First 30 (49%) 
     Second 25 (40%) 
     Third 7 (11%) 
Graft manipulation  
     No 27 (44%) 
     CD34 7 (11%) 
     CD8 28 (45%) 
DLI  
     No 29 (47%) 
     Yes 33 (53%) 
Acute GVHD  
     0-1 42 (68%) 
     2 17 (27%) 
     3-4 3 (5%) 
Chronic GVHD  
     None 42 (68%) 
     Limited 11 (18%) 
     Extensive 9 (14%) 
Corticosteroids  
     No 26 (42%) 
     Yes 36 (58%) 
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Table 2. Absolute numbers and proportions (% of patients at risk) of patients with infectious 
complications after transplantation. Only infections before disease progression were considered. 
 
All infections 
≥ 1 infection 48 (77%) 
≥ 2 infections 31 (50%) 
≥ 3 infections 18 (29%) 
≥ 4 infections 11 (18%) 
≥ 5 infections 8 (13%) 
Infections before day 30 
≥ 1 infection 21 (34%) 
≥ 2 infections 6 (10%) 
≥ 3 infections 0 (0%) 
Infections day 31-day 100 
≥ 1 infection 27 (48%) 
≥ 2 infections 10 (18%) 
≥ 3 infections 5 (9%) 
Infections day 101-day 365 
≥ 1 infection 30 (59%) 
≥ 2 infections 12 (23%) 




Table 3. Number of infections (N per patient at risk) according to time after transplantation. Only 
infections before disease progression were considered. 
  
 Days 0-30 Days 31-100 Days 101-365 Days > 365 
N patients at risk 62 56 51 20 
All infections 21 (0.34) 38 (0.68) 41 (0.80) 10 (0.50) 
Infections by agent     
Viral  1 (0.02) 1 (0.02) 5 (0.10) 4 (0.20) 
Fungal  2 (0.03) 3 (0.05) 5 (0.10) 1 (0.05) 
Bacterial  17 (0.27) 33 (0.59) 28 (0.55) 5 (0.25) 
Parasitic  0 (0.00) 0 (0.00) 1 (0.02) 0 (0.00) 
Unknown 1 (0.02) 1 (0.02) 2 (0.04)  0 (0.00) 
Total 21 38 41 10 
Infections by type     
Bacteraemia 5 (0.08) 16 (0.29) 17 (0.33) 1 (0.05) 
IP 1 (0.02) 1 (0.02) 3 (0.06) 0 (0.00) 
Other pneumonia 4 (0.06) 9 (0.16) 8 (0.16) 5 (0.25) 
Upper resp. tract 0 (0.00) 4 (0.07) 2 (0.04) 2 (0.10) 
Abdominal 2 (0.03) 2 (0.04) 2 (0.04) 1 (0.05) 
Genito-urinary 1 (0.01) 1 (0.02) 1 (0.02) 0 (0.00) 
Zoster/varicella 0 (0.00) 0 (0.00) 2 (0.04) 1 (0.05) 
Skin (other) 0 (0.00) 1 (0.02) 2 (0.04) 0 (0.00) 
CNS 0 (0.00) 1 (0.02) 1 (0.02) 0 (0.00) 
Miscellaneous 0 (0.00) 0 (0.00) 1 (0.02) 0 (0.00) 
FUO 8 (0.13) 3 (0.05) 2 (0.04) 0 (0.00) 
Total 21 38 41 10 
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Table 4. CMV reactivation and CMV disease. 
 
CMV status 





Negative Negative 15 0 (0%) 0 (0%) 
Negative Positive 11 4 (36%) 1 (9%) 
Positive Negative 20 14 (70%) 5 (25%) 
Positive Positive 16 14 (88%) 5 (31%) 




Legends to the figures 
 
Figure 1. Actuarial incidence of infections (A), bacteraemias (B) and infections other than 
bacteraemias (C). 
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Figure 2 
